Pharmacogenomics and uncontrolled arterial hypertension

AUTHOR(S) / AUTOR(I): Miroslav Radenkovic 

Download Full Pdf   

DOI: 10.46793/KARNEF25.336R

ABSTRACT / SAŽETAK:

Arterial hypertension is the principal source of chronic noncommunicable pathological disorders. Low adherence, ineffective therapy, and a frequent lack of distinct clinical signs are linked to the excessive occurrence of uncontrolled and undiagnosed clinical cases. Resistant hypertension (RH) is a condition where blood pressure remains elevated and uncontrolled, despite the use of three or more antihypertensive medications, including a diuretic, at optimal doses. Thus, it is essential to develop individualized treatment plans, considering patients’ overall health, medication tolerability, and drug-related potential side effects. In order to improve control of blood pressure in RH, personalized treatment may be a unique strategy, where the pharmacogenomics approach would be of immense importance. Heritability is thought to be responsible for significant percentage of the variation in blood pressure across individuals, where inter-individual genetic variability could notably contribute to the limited effectiveness of some treatments, as well. Accordingly, comprehensive therapies would be the best option for treating hypertension and RH since it is evident that the condition is not monogenetic regulated. Given the previous facts, this paper tends to provide basic information on the current knowledge in pharmacogenomics research related to new therapeutic possibilities for uncontrolled hypertension.

 KEYWORDS / KLJUČNE REČI:

pharmacogenomics, hypertension, uncontrolled hypertension, genetic variability

REFERENCES / LITERATURA:

• Budreviciute A, Damiati S, Sabir DK, Onder K, Schuller-Goetzburg P, Plakys G, Katileviciute A, Khoja S, Kodzius R. Management and prevention strategies for non-communicable diseases (NCDs) and their risk factors. Frontiers in public health. 2020 Nov 26;8:574111.
• Düsing R. Overcoming barriers to effective blood pressure control in patients with hypertension. Current medical research and opinion. 2006 Aug 1;22 (8): 1545-53.
• Burnier M, Egan BM. Adherence in hypertension: a review of prevalence, risk factors, impact, and management. Circulation research. 2019 Mar 29; 124(7): 1124-40.
• Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018 Nov; 72(5): e53-90.
• Almeida MQ, Silva GV, Drager LF. What is the most common cause of secondary hypertension?: An interdisciplinary discussion. Current hypertension reports. 2020 Dec;22:1-9.
• Parodi R, Brandani L, Romero C, Klein M. Resistant hypertension: diagnosis, evaluation, and treatment practical approach. European Journal of Internal Medicine. 2024, 123: 23-28.
• Xiao ZL, Yang M, Chen XB, Xie XM, Chen MF. Personalized antihypertensive treatment guided by pharmacogenomics in China. Cardiovascular Diagnosis and Therapy. 2022 Oct; 12(5):635.
• Cooper-DeHoff RM, Johnson JA. Hypertension pharmacogenomics: in search of personalized treatment approaches. Nature Reviews Nephrology. 2016 Feb;12 (2): 110-22.
• Singh DB. Pharmacogenomics: clinical perspective, strategies, and challenges. Translational Bioinformatics and Its Application. 2017:299-333.
• Sarwar E. Clinical Significance of Precision Medicine–Genomics and Pharmacogenomics (PGx). InGlobal Perspectives on Precision Medicine: Ethical, Social and Public Health Implications 2023 Apr 5 (pp. 33-54). Cham: Springer International Publishing.
• Malsagova KA, Butkova TV, Kopylov AT, Izotov AA, Potoldykova NV, Enikeev DV, Grigoryan V, Tarasov A, Stepanov AA, Kaysheva AL. Pharmacogenetic testing: a tool for personalized drug therapy optimization. Pharmaceutics. 2020 Dec 19; 12(12): 1240.
• Pirmohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends in pharmacological sciences. 2001 Jun 1; 22(6): 298-305.
• Zhang G, Nebert DW. Personalized medicine: Genetic risk prediction of drug response. Pharmacology & therapeutics. 2017 Jul 1; 175:75-90.
• …